Business
Novo Nordisk Shares Rise Despite 2025 Outlook Downgrade Amid Weight-Loss Drug Market Pressures
Shares in Novo Nordisk surged on Wednesday after the Danish pharmaceutical giant posted stronger-than-expected first-quarter earnings, even as it lowered its growth outlook for 2025 due to mounting competition in the weight-loss drug market.
The company, best known for its diabetes and obesity treatments, reported a 20% year-on-year rise in net profit to 38.8 billion Danish kroner (€5.2 billion), with net sales up 18% to 78.1 billion kroner (€10.5 billion). Both figures exceeded analyst expectations, driven by robust demand for obesity and diabetes medications.
Despite the upbeat results, Novo Nordisk cut its full-year guidance. The firm now expects 2025 sales growth of 13–21%, down from its earlier projection, and operating profit growth between 16–24% at constant exchange rates—both lowered by several percentage points.
“We have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US,” CEO Lars Fruergaard Jørgensen said in a statement. “We are actively focused on preventing unlawful and unsafe compounding and on efforts to expand patient access to our GLP-1 treatments.”
Still, shares rose 4.4% at the opening of European trading, though the stock remains down 26% since the start of the year. In contrast, main U.S. competitor Eli Lilly has seen a more stable stock performance in 2025.
A key pressure point for Novo Nordisk is the U.S. market, where demand for GLP-1-based weight-loss treatments like Wegovy has outpaced supply. Under FDA policy, compounding pharmacies were permitted to produce alternative versions of drugs in short supply, allowing smaller rivals to offer cheaper options. Although the FDA declared shortages over earlier this year, it granted a grace period until May 22 for compounded versions to remain in circulation.
In response, Novo Nordisk slashed Wegovy’s price by more than half on its online platform, NovoCare, mirroring similar price cuts by Eli Lilly.
In its outlook, Novo Nordisk highlighted the continued global rollout of Wegovy, noting there are an estimated one billion people living with obesity worldwide, yet only a fraction are receiving treatment. CFO Karsten Munk Knudsen said he expects Wegovy sales to pick up further in the third quarter.
Meanwhile, the company announced the completion of its REDEFINE 2 trial for its next-generation drug, CagriSema, which showed a 15.7% weight reduction. While the results fell short of the 25% reduction some had hoped for, Novo Nordisk aims to file for regulatory approval early next year.
The company also said it has filed for U.S. approval of a new oral formulation of semaglutide, which could become the first oral GLP-1 drug for obesity treatment.
Despite market headwinds, Novo Nordisk remains optimistic about future growth in a highly competitive but fast-expanding global obesity market.
Business
Iran Conflict Sparks Global Fertiliser Crunch, Raising Fears for Food Security
The war involving Iran and the continued blockade of the Strait of Hormuz are beginning to ripple through global agriculture, with rising fertiliser costs threatening food production and pushing farmers under increasing financial strain.
A new World Bank report warns that soaring energy prices and disrupted trade routes have created a severe fertiliser squeeze, driving affordability for farmers to its lowest level in four years. The crisis is being fuelled largely by a sharp rise in natural gas prices, a key ingredient in the production of nitrogen-based fertilisers.
Because fertiliser production is closely tied to energy markets, any spike in gas prices quickly translates into higher costs for farmers. That dynamic is now raising concerns about the impact on future harvests, particularly in regions already facing economic and food security challenges.
European agriculture ministers are reportedly discussing emergency measures to shield farmers from escalating costs and to protect grain production for next year. While Europe is not currently facing an immediate supply shortage, industry groups say the pressure on farm finances is intensifying.
A spokesperson for Fertilisers Europe said the continent remains relatively well supplied, thanks to strong domestic production and high import levels in recent months. Europe typically meets around 70% of its fertiliser demand through its own output.
However, the organisation warned that farmers are operating on increasingly narrow margins. It called for targeted support from European Union institutions while also ensuring that assistance does not undermine the competitiveness of the region’s fertiliser industry.
The situation is more severe outside Europe. According to the UN Food and Agriculture Organization, shipping disruptions through the Strait of Hormuz have caused significant fertiliser shortages across Asia, the Middle East and parts of Africa.
Countries including India, Bangladesh, Sri Lanka, Egypt, Sudan and several nations in sub-Saharan Africa are facing rising costs, reduced availability and growing risks to food security.
Analysts warn that if farmers cut fertiliser use to save money, crop yields could fall sharply in the next planting season. Research from the International Food Policy Research Institute suggests that reduced application rates would likely lower global grain production and tighten food supplies.
The FAO’s Food Price Index has already begun to rise, reflecting mounting concerns over input costs and supply disruptions. Higher transport expenses and logistical challenges linked to the conflict are expected to place additional upward pressure on food prices in the months ahead.
For many developing economies already struggling with inflation, the impact could be especially severe. Policymakers may face difficult choices as they seek to balance economic stability with food affordability.
Experts say the crisis underscores the importance of securing not only food supplies, but also the essential inputs that make food production possible. Without a stabilisation of energy markets and a restoration of normal shipping routes, the effects of the Iran conflict could linger far beyond the battlefield.
Business
Oil Markets Jolt as UAE Exits OPEC Amid Strait of Hormuz Crisis
Business
UAE’s OPEC Exit Marks New Chapter for Gulf Energy Strategy
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
